Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New anxiety drug shows promise in early trial

NCT ID NCT06653296

Symptom relief Sponsor: Engrail Therapeutics INC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study tested a new drug called ENX-102 in 38 adults with generalized anxiety disorder. Participants received either a low, mid, or high dose of ENX-102 or a placebo for six weeks. The goal was to check safety and find the best dose. The trial is now complete.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ENX-102
What this could lead to
If successful, this could point toward a new treatment option for generalized anxiety disorder with a potentially better safety or tolerability profile.
What could go wrong
This is a small, early-phase trial with only 38 participants. The drug may not prove more effective than placebo, and side effects could limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

38 people

The number who actually took part.

Started

Dec 2024

Finished

Jun 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Male or female, inclusive of any gender identity, aged 18 to 65 years, inclusive * Diagnosed with GAD according to the DSM-V, confirmed by MINI * Experiencing clinically significant generalized anxiety as measured by HAM-A score ≥18 and at least moderately severe core symptoms of anxious mood and tension as measured by HAM-A Items 1 and 2, respectively, with scores each ≥2 Key Exclusion Criteria: * Clinically predominant psychiatric diagnosis other than GAD per the MINI * Any past/lifetime or current diagnosis of a neurocognitive disorder or psychotic disorder, or current posttraumatic stress disorder, obsessive compulsive disorder, or bipolar disorder * Ingested prohibited medication within 5 half-lives prior to Day 1 * Current or recent moderate or severe substance use disorder as assessed by the MINI * Unwilling or unable to abstain from alcohol or other recreational psychoactive substances such as marijuana during participation in the trial * Has significant progressive disorders or unstable medical conditions * Is unable to comply with the requirements of the study or, in the opinion of the Investigator, is unsuitable for the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for General anxiety disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder generalized anxiety disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

General anxiety disorder

Contacts and locations

Locations

  • MAC Clinical Research

    Liverpool, UK, United Kingdom

  • MAC Clinical Research

    Blackpool, United Kingdom

  • MAC Clinical Research

    Manchester, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.